With Regeneron's covid antiviral "antibiotic" having limited effect against the omicron variant and sotrovimab being in limited supply, my bet is the NIH would welcome another antiviral. Especially one with possible pancorona virus effects.

https://www.yahoo.com/news/omicron-variant-th...58773.html

https://www.reuters.com/business/healthcare-p...021-12-14/

https://www.globenewswire.com/en/news-release...eutic.html

Pfizer's new oral antiviral effects may begin to wane 5 days post the onset of symptoms.

https://www.pfizer.com/news/press-release/pre...dy-results

IMO Brilacidin's chances to be included in the NIH ACTIV trial have improved.

https://www.ipharminc.com/press-release/2021/...-19-trials

How many mutants will follow delta and omicron? What medications will be resistant to the new Covid variants?

GLTA,

Farrell